ArticleScientific reports2025
Lysyl oxidase mediates regeneration of chondrocytes and extracellular matrix in the construction of tissue-engineered cartilage in vitro.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Oxygen Consumption Rate-Defined Phases Couple Metabolism to Matrix Dynamics in Chondrocyte-Mesenchymal Stromal Cell Co-Culture.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Spatiotemporal heterogeneity of neutrophil extracellular traps in hepatocellular carcinoma microenvironment and targeted therapy progress.Journal of translational medicine · 2026Review
- Nanozymes for extracellular matrix and cell sheet engineering: biomedical potential and complementary enzymatic strategies.Frontiers in molecular biosciences · 2026Review
- Advances in Injectable miRNA-Loaded Nanocomposite Hydrogel Systems for Cartilage Repair in KOA.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cartilage tissue engineering affords great promise for cartilage tissue regeneration in clinical practice. Unfortunately, in vitro engineered cartilage falls short of mechanical properties compared to natural cartilage, which has not yet become the mainstream of cartilage defect repair. Notably, the collagen fiber structure in the extracellular matrix (ECM) of chondrocytes accounts for the mechanical properties of engineered cartilage. Specifically, massive collagen fibers in ECM are covalently cross-linked by lysyl oxidase (LOX) to form a rigid cross-linked structure, contributing to certain mechanical properties. Accordingly, LOX may be a key enzyme for improving the mechanical properties of tissue-engineered cartilage in vitro. As reported, transforming growth factor-β1 (TGF-β1) can activate LOX via the SMAD-independent MAPK pathway, and β-aminopropionitrile (BAPN), an irreversible inhibitor of LOX, directly represses the cross-linking between macromolecules in the ECM of chondrocytes. In the present study, we intervened in cartilage regeneration in vitro using the aforementioned activator and inhibitor of LOX, thereby evaluating the quality and mechanical properties of tissue-engineered cartilage and further investigating the role of LOX in cartilage regeneration in vitro. Our results demonstrated that TGF-β1 improved the mechanical properties of cartilage in vitro at both two-dimensional and three-dimensional constructs by activating LOX. Therefore, further experimental studies are warranted to probe the activators of LOX and their mechanisms in cartilage regeneration in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.